Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28444822 | 0.99 | EGFR (0.52) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL6601404 | 0.98 | EGFR (0.54) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL25421283 | 0.97 | EGFR (0.53) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| Hydrochloric Acid SCHEMBL21814218 | 0.97 | EGFR (0.56) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL3422030 | 0.97 | EGFR (0.53) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| Bromide SCHEMBL14247934 | 0.96 | EGFR (0.52) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL10317072 | 0.93 | ALDH1A1 (0.54) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL25134221 | 0.93 | EGFR (0.50) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL17921386 | 0.91 | EGFR (0.48) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL5054607 | 0.91 | EGFR (0.48) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001052899-A1 | CHELATING AGENTS AND METHOD FOR THEIR USE AS TANDEM METAL CHELATORS AND HYDROPHILIC SPACERS FOR MEDICAL DIAGNOSIS AND THERAPY | MALLINCKRODT INC. (US) | 2001-07-26 | — | — | WO | claimed |
| EP-2495563-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | Fujifilm RI Pharma Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | FUJIFILM RI PHARMA CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| WO-2008144728-A1 | CONJUGATES WHICH BIND A BLOOD PROTEIN SUCH AS HUMAN SERUM ALBUMIN AND METHODS OF USING THE SAME IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2008-11-27 | — | — | WO | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
| US-20080124270-A1 | Compounds Useful as Metal Chelators | BRACCO IMAGING S.P.A. (IT) | 2008-05-29 | — | — | US | disclosed |
| US-20080124270-A1 | Compounds Useful as Metal Chelators | BRACCO IMAGING S.P.A. (IT) | 2008-05-29 | — | — | US | disclosed |
| US-20080124270-A1 | Compounds Useful as Metal Chelators | BRACCO IMAGING S.P.A. (IT) | 2008-05-29 | — | — | US | disclosed |
| US-20070167615-A1 | Macrocyclic oligonucleotide labeling reactants and conjugates derived thereof | WALLAC OY (FI) | 2007-07-19 | — | — | US | disclosed |
| US-20070167615-A1 | Macrocyclic oligonucleotide labeling reactants and conjugates derived thereof | WALLAC OY (FI) | 2007-07-19 | — | — | US | disclosed |
| EP-1699466-A2 | NEW COMPOUNDS USEFUL AS METAL CHELATORS | Bracco Imaging, S.P.A. (IT) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005062828-A2 | NEW COMPOUNDS USEFUL AS METAL CHELATORS | BRACCO IMAGING S.P.A. (IT) | 2005-07-14 | — | — | WO | disclosed |
| WO-2001052898-A9 | METHODS FOR INCORPORATING METAL CHELATORS AT CARBOXYL-TERMINAL SITE OF PEPTIDES | MALLINCKRODT INC (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2001052898-A1 | METHODS FOR INCORPORATING METAL CHELATORS AT CARBOXYL-TERMINAL SITE OF PEPTIDES | MALLINCKRODT INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001052900-A2 | NOVEL ORTHOGONALLY PROTECTED AMINO ACID CHELATORS FOR BIOMEDICAL APPLICATIONS | MALLINCKRODT INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | BTD, HLCS, BOLA2; BOLA2B | EGFR 689/4885ALDH1A1 1007/4885SMN1; SMN2 2929/4885 |
| US-20070167615-A1 | Macrocyclic oligonucleotide labeling reactants and conjugates derived thereof | POLRMT, RTCB, POLM | EGFR 792/4885ALDH1A1 2550/4885SMN1; SMN2 2654/4885 |
| US-20080124270-A1 | Compounds Useful as Metal Chelators | PAICS, PHOSPHO1, PPIP5K2 | EGFR 3022/4885ALDH1A1 4035/4885SMN1; SMN2 3701/4885 |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | NISCH, CNDP2, MYADM | EGFR 4518/4885ALDH1A1 1641/4885SMN1; SMN2 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.